Team discovers mechanism responsible for tumor invasion in brain cancer

April 9, 2015
Investigators Discover Mechanism Responsible for Tumor Invasion in Brain Cancer
Invasion assays using Glioblastoma (GBM) cells on the left lacking Id4, in comparison to the same cells being genetically engineered to express Id4 on the right. Every invaded cell in this assay is colored green and the assay showed that the cells on the left, lacking Id4, invaded much more than the cells on the right in which there was forced expression of Id4.

A neuro-oncology research team at Dartmouth's Norris Cotton Cancer Center, led by the Director Mark A. Israel, MD with first author Gilbert J. Rahme, PhD, recently identified the transcription factor Id4 as a suppressor of tumor cell invasion in glioblastoma. Their paper, "Id4 suppresses MMP2-mediated invasion of glioblastoma-derived cells by direct inactivation of Twist1 function," was recently published in Oncogene. A key finding was the mechanism by which Id4 silences matrix metalloproteinase 2 (MMP2), determined to be inhibition of the protein Twist1 that is required for MMP2 expression.

"This finding suggests a novel therapeutic target to decrease invasion of in patients and may also provide a novel biomarker that could help predict survival of patients with glioblastoma," explained Israel.

Glioblastoma is the most lethal form of and leads to death in patients by invading the brain tissue in a process that allows single cells to move through normal brain tissue, which makes complete surgical removal of the tumor impossible. Israel and his team sought to understand the mechanisms that drive tumor invasion of normal tissue in glioblastoma.

Using data from The Cancer Genome Atlas (TCGA), the Dartmouth team demonstrated that Id4 expression correlates with survival of glioblastoma patients and inversely correlates with MMP2 expression. The data suggests that the upregulation of MMP2 resulting from decreased Id4 expression in multiforme (GBM) may contribute to the morbidity and mortality of GBM patients.

This study used Dartmouth's Shared Resources including Microscopy and Molecular Biology. "Using the core facilities greatly facilitated the conduct of the work saving time and reducing cost," Rahme said. All 14 of Dartmouth's Shared Resources are available to outside investigators by arrangement.

"Conventional drugs targeting the enzymes encoded by MMP genes have not been successful in the clinic due to adverse side effects," said Rahme. "We believe that proteins in the pathway that controls the expression of MMP2 are likely to be better therapeutic targets. Targeting Twist1 might silence MMP2 and decrease tumor invasion, which will help patients with GBM. Furthermore, the of Id4 may serve as a tumor biomarker that can predict the degree of tumor infiltration."

Looking forward, the therapeutic targets revealed in this study to be actors in tumor invasion need to be further characterized as drug targets and, if possible, therapeutically inhibited. Their pursuit of Id4 as a biomarker for with GBM continues in hopes of making useful predictions of and survival.

Explore further: Metabolic compensation underlies drug resistance in glioblastoma

Related Stories

Metabolic compensation underlies drug resistance in glioblastoma

March 23, 2015
Gliobststoma (GBM) is a highly aggressive brain tumor that is resistant to many conventional cancer therapies. The kinase mTOR induces pathways that are aberrantly activated in GBM. However, mTOR inhibitors have not shown ...

Researchers identify protein pathway involved in brain tumor stem cell growth

February 26, 2015
Glioblastomas are a highly aggressive type of brain tumor, with few effective treatment options. Moffitt Cancer Center researchers are one step closer to understanding glioblastoma development following the identification ...

Study identifies possible new target for future brain cancer drugs

February 27, 2014
A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat the most frequent and lethal form of brain cancer, according to a new study by researchers at The Ohio ...

Glioblastoma: Study ties three genes to radiation resistance in recurrent tumors

February 3, 2015
A new study identifies three genes that together enable a lethal form of brain cancer to recur and progress after radiation therapy.

Researchers identify potential therapeutic target for deadly brain cancer

April 8, 2014
Researchers from the Geisel School of Medicine at Dartmouth will present a scientific poster on Tuesday, April 8, 2014 at the American Association of Cancer Researchers conference in San Diego, CA. The research identifies ...

Cancer genes deactivated in deadly brain cancer

April 3, 2015
Northwestern Medicine scientists have identified a small RNA molecule called miR-182 that can suppress cancer-causing genes in mice with glioblastoma mulitforme (GBM), a deadly and incurable type of brain tumor.

Recommended for you

Tracking how multiple myeloma evolves by sequencing DNA in the blood

December 10, 2017
Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, ...

Landmark CAR-T cancer study published

December 10, 2017
Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

Study finds emojis promising tool for tracking cancer patients' quality of life

December 10, 2017
In findings presented to the American Society of Hematology, Mayo Clinic researchers found that using emojis instead of traditional emotional scales were helpful in assessing patients' physical, emotional and overall quality ...

Study explores use of checkpoint inhibitors after relapse from donor stem cell transplant

December 10, 2017
Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial ...

Blood test may help predict which breast cancers will recur

December 8, 2017
A blood test five years after breast cancer treatment helped identify some women who were more likely to relapse, long before a lump or other signs appeared, a preliminary study found.

Alcohol-abuse drug Antabuse kills cancer cells

December 8, 2017
A new study in Nature by an international team including researchers from Karolinska Institutet, reports that the alcohol-abuse drug Antabuse is effective against cancer. The study also identifies a potential mechanism of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.